

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/185784 A4

(43) International Publication Date
23 September 2021 (23.09.2021)

(51) International Patent Classification:

G01N 33/68 (2006.01) G01N 33/74 (2006.01)
A61K 38/22 (2006.01)

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2021/056572

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

15 March 2021 (15.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20163406.0	16 March 2020 (16.03.2020)	EP
62/990,171	16 March 2020 (16.03.2020)	US
63/015,102	24 April 2020 (24.04.2020)	US
20179738.8	12 June 2020 (12.06.2020)	EP
21153847.5	27 January 2021 (27.01.2021)	EP
63/142,370	27 January 2021 (27.01.2021)	US

Published:

— with international search report (Art. 21(3))
— with amended claims (Art. 19(1))
— with sequence listing part of description (Rule 5.2(a))

Date of publication of the amended claims:

25 November 2021 (25.11.2021)

(71) Applicants: SPHINGOTEC GMBH [DE/DE]; Neuendorfstraße 15A, 16761 Hennigsdorf (DE). ADRENOMED AG [DE/DE]; Neuendorfstraße 15A, 16761 Hennigsdorf (DE).

(72) Inventor: BERGMANN, Andreas; Am Rosenanger 78, 13465 Berlin (DE).

(74) Agent: KILGER, Ute; BOEHMERT & BOEHMERT Anwaltspartnerschaft mbB, Hollerallee 32, 28209 Bremen (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: PRO-ADRENOMEDULLIN OR FRAGMENT THEREOF IN PATIENTS INFECTED WITH CORONA VIRUS AND TREATMENTS WITH BINDER AGAINST ADRENOMEDULLIN

(57) Abstract: Subject matter of the present invention is a method for (a) diagnosing or predicting the risk of life-threatening deterioration or an adverse event or (b) prognosing the severity or (c) predicting or monitoring the success of a therapy or intervention in a patient infected with a Corona virus, the method comprising: - determining the level of pro-Adrenomedullin (SEQ ID No. 31) or fragment thereof in a sample of bodily fluid of said patient, - comparing said level of pro-Adrenomedullin or fragment thereof to a predetermined threshold or a previous level of pro-Adrenomedullin or fragment thereof, and - correlating said level of pro-Adrenomedullin or fragment thereof with the risk of life-threatening deterioration or an adverse event, or - correlating said level of pro-Adrenomedullin or fragment thereof with the severity, or - correlating said level of pro-Adrenomedullin or fragment thereof with the success of a therapy or intervention, wherein said pro-Adrenomedullin or fragment thereof is selected from the group consisting of PAMP (SEQ ID No. 32), MR-proADM (SEQ ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34). Subject matter of the present invention is an Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy or intervention in a patient in a patient infected with a Corona virus.

WO 2021/185784 A4